Brigatinib AP26113

Min.Order / FOB Price:Get Latest Price

10 Gram	Negotiable

10 Gram

Negotiable

Min.Order :10 Gram
Purity: 99%
Payment Terms : L/C,T/T,,MoneyGram

Keywords

AP26113 Brigatinib CAS 1197958-12-5

Quick Details

Appearance:white powder
Application:AP26113 (also known as Brigatinib) is an investigated small molecule for targeted cancer therapy. It is a potent dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor
PackAge:As customer request
ProductionCapacity:100|Kilogram|Week
Storage:room temp
Transportation:By Sea/Air/Courier

Superiority:

Triumph Chemical Title

Triumph Company Office picture

Triumph Company advantage

Triumph Testing title picture

Triumph Testing way

Welcome to contact us

Lorcaserin(856681-05-5)is an orally administered agent and a selective 5-HT2C receptor agonist for the treatment of obesity. It had been approved for marketing in US by FDA on 27 June in 2012. In clinical studies, lorcaserin has demonstrated efficacy in obese and overweight populations by promoting weight loss and improving metabolic parameters, and it is well tolerated.

Details:

AP26113

CAS:	1197958-12-5
MF:	C27H36ClN6O4P
MW:	575.039301
Appearance:	White solid
Assay:	99%
Boiling point:	737.6±70.0 °C(Predicted)
desnity:	1.29±0.1 g/cm3(Predicted)
Uses: AP26113 (also known as Brigatinib) is an investigated small molecule for targeted cancer therapy. It is a potent dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It is mainly under investigation for its treatmentefficacy on non-small cell lung cancer (NSCLC) where ALK is activated and EGFP mutations frequently occur.

View All

Visit Store

Brigatinib AP26113